PUBLICATIONS

1. Manuscripts.

In Print


45. **Swords R**, O'Rafferty C, Giles F, Browne P. Spurious elevation of the cerebrospinal fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy. Leukemia. 2008 Dec;22(12):2277-8.


57. Murphy PT, Quinn JP, O'Donghaile D, **Swords R**, O'Donnell JR. Myelodysplastic patients with raised percentage of hypochromic red cells have evidence of functional iron deficiency Ann Hematol. 2006 Jul;85(7):455-7.


In Press

2. Presentations to Learned Societies

Poster Presentations


10. E O'Dwyer, R Swords, P LeCoutre, M McMullin, S Langabeer, S Padmanabhan, E Kent, M Parker, B Moulton, K Egan, E Conneally. Nilotinib 300mg Twice Daily is Effective and Well Tolerated as First Line Treatment of Ph+ Chronic Myeloid Leukemia in First Chronic Phase – Preliminary Results of the ICORG Phase II Study. EHA 2010

11. Ronan Swords, Kevin Kelly, Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, Peter Smith, Kelly Oberhau, Michael O'Dwyer, David Rizzieri, Francis Giles, Carew Jennifer. MLN4924, A Novel First in Class Inhibitor of the NEDD8 Activating Enzyme (NAE), has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia (AML). Fifth Internation Conference SUMO, Ubiquitin, UBL Proteins: Implications for Human Diseases, M.D. Anderson Cancer Center, Houston, TX, February 2010

12. Ronan Swords, Kevin Kelly, Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, Peter Smith, Michael O'Dwyer, David Rizzieri, Francis Giles, Carew Jennifer. MLN4924, A Novel First in Class Inhibitor of the NEDD8 Activating Enzyme (NAE), has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia (AML). EHA 2009


22. Kelly K., Swords R., Mahalingam D., Nawrocki S., Giles F., Carew J. The Aurora A Kinase Inhibitor MLN8237 has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib. American Society of Hematology Meeting 2009

23. Sanjy Bansal, Hima Bansal, Manjeet Rao, Ronan Swords, Kevin Kelly, Jennifer Carew, Kelvin Lee, Frank Giles, Swaminathan Padmanabhan. WT1 interacts with the chaperone protein HSP90 and this regulates its expression. AACR 2009

25. Devalingam Mahalingam, Ernest Medina, Ronan Swords, Kevin Kelly, Jennifer Carew, Francis Giles, Steffan Nawrocki. The combination of Sutent with the PIM Kinase Inhibitor SGI-1776 has Synergistic Activity in Pre-Clinical Models of Renal Cell Carcinoma. AACR 2009


27. J. Krawczyck, T Murphy, R Swords, T Meenaghan, M O Dwyer. Novel Treatment of Multicentric Castleman’s Disease with Lenalidomide. EHA 2008 (abstract)


34. Swords R, O’Dalaigh A, Vandenbergh E, Hennessy B. Occupational Exposure to Pesticides as a Risk Factor for Aggressive Non-Hodgkins Lymphoma – A Case Study. Haematology Association of Ireland, Belfast, Ireland, Nov. 2005


Oral Presentations

1. Disruption of NEDD8 Protein Conjugation: A Novel Therapeutic Strategy for the Myeloid Neoplasms. Grand Rounds Invited Speaker, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, 2013


5. The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study Blood. ASH Annual Meeting, Nov 2010, 116: 658.


20. Advancement of Patient Care in Philadelphia Chromosome Positive Chronic Myeloid Leukemia. *Chronic Myeloid Leukemia Pocket Meeting, Las Vegas, October 2009*